Bristol Myers Squibb: new results for reblozyl
(CercleFinance.com) - Bristol Myers Squibb has announced top-line results from the phase 3 COMMANDS study, a randomised, open-label trial evaluating Reblozyl versus the erythropoiesis-stimulating agent (ESA) epoetin alfa.
A trial conducted for the treatment of anaemia in adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) requiring red blood cell (RBC) transfusions and who have never received an ESA.
Results showed that nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with a concomitant increase in haemoglobin compared to epoetin alfa, including in clinically relevant subgroups.
Reblozyl demonstrated a durable response, with a median transfusion independence of almost 2.5 years, "1 year longer than epoetin alfa", the company states.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
A trial conducted for the treatment of anaemia in adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) requiring red blood cell (RBC) transfusions and who have never received an ESA.
Results showed that nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with a concomitant increase in haemoglobin compared to epoetin alfa, including in clinically relevant subgroups.
Reblozyl demonstrated a durable response, with a median transfusion independence of almost 2.5 years, "1 year longer than epoetin alfa", the company states.
Copyright (c) 2023 CercleFinance.com. All rights reserved.